What is Leerink Partnrs’ Estimate for UTHR FY2024 Earnings?

United Therapeutics Co. (NASDAQ:UTHR) – Leerink Partnrs reduced their FY2024 EPS estimates for United Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will earn $25.09 per share for the year, down from their previous estimate of $25.94. The consensus estimate for United Therapeutics’ current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q1 2025 earnings at $6.95 EPS, Q2 2025 earnings at $7.31 EPS, Q3 2025 earnings at $7.81 EPS, FY2025 earnings at $29.77 EPS, FY2026 earnings at $31.02 EPS, FY2027 earnings at $30.53 EPS and FY2028 earnings at $32.83 EPS.

Several other analysts have also commented on the stock. The Goldman Sachs Group increased their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. LADENBURG THALM/SH SH increased their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. UBS Group increased their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, TD Cowen increased their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Trading Up 4.9 %

Shares of UTHR opened at $370.74 on Wednesday. The firm’s 50-day moving average is $361.99 and its two-hundred day moving average is $358.32. The firm has a market capitalization of $16.55 billion, a P/E ratio of 16.28, a PEG ratio of 0.92 and a beta of 0.57. United Therapeutics has a twelve month low of $211.61 and a twelve month high of $417.82.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Parallel Advisors LLC raised its stake in United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 30 shares during the last quarter. Signaturefd LLC raised its stake in United Therapeutics by 4.7% during the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after purchasing an additional 30 shares during the last quarter. Great Lakes Advisors LLC raised its stake in United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after purchasing an additional 31 shares during the last quarter. Oregon Public Employees Retirement Fund raised its stake in United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock valued at $3,214,000 after purchasing an additional 33 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its stake in United Therapeutics by 0.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock valued at $1,761,000 after purchasing an additional 39 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 121,864 shares of company stock valued at $44,516,965 over the last quarter. Company insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.